Earnings call transcript: Omron Q4 2025 misses forecasts, stock dips

OMRON reported FY2025 revenue of 767.4 billion JPY (+7.3% YoY) and operating income of 59.9 billion JPY (+12.1%), but the headline fourth-quarter print missed expectations with EPS of 71.93 JPY vs. 86.59 JPY forecast and revenue of 153.06 billion JPY vs. 240.78 billion JPY. Shares fell 2.95% after hours as investors weighed strong AI-driven growth in Industrial Automation against weakness in Healthcare, tariff and supply-chain risks, and discontinued-operations drag. Management guided FY2026 net revenue to 820 billion JPY (+6.9%) and lifted the annual dividend to 110 JPY.

Analysis

The core read-through is that OMRON is transitioning from a cleanup story into a capex-leverage story, but the equity is still pricing it like a steady industrial compounder. The highest-quality signal is not the headline miss; it is the combination of accelerating order momentum in automation, explicit visibility into supply for next year, and management’s willingness to absorb near-term margin drag to defend growth. That usually marks the phase where the multiple can expand before the P&L fully catches up, especially if AI-linked demand remains a small enough share of revenue to avoid a crowded consensus trade but large enough to move bookings.

The second-order implication is that the market may be underestimating the operating leverage embedded in the customer-base rebuild. If AI-related demand is only low-teens of revenue but roughly half of order growth, then the true upside is broader than semicap exposure: distributors, integrators, and regional automation peers that rely on the same end-market recovery should see the same demand inflection with less company-specific execution risk. Conversely, healthcare looks like a classic low-growth, price-sensitive cash generator where share gains are possible but margin expansion will be constrained; that makes it a funding source for the automation pivot rather than a standalone re-rating engine.

The main risk is timing, not direction. Near-term margin compression from mix, logistics, and component inflation can easily overwhelm the bull case if investors focus on quarterly earnings rather than order book conversion, and any disruption tied to Middle East-related supply or resin components would hit sentiment quickly because the stock has already rerated hard over six months. The contrarian angle is that the recent selloff on the miss may be too shallow if the company is effectively signaling a 12-24 month investment cycle: if the market wanted clean current earnings, it would own higher-quality mature automation peers, but if the market wants torque to a multi-year industrial AI buildout, OMRON may be one of the few names with both leverage and self-help.

Key Decisions for Investors

• Go long OMRON on a 1-3 month horizon on post-earnings weakness, targeting a re-rate as order momentum is recognized; use a tight stop if management commentary turns cautious on Q1/first-half conversion.
• Pair trade: long OMRON / short a slower-growth industrial automation peer with less AI exposure over the next 6 months; thesis is that OMRON’s booking leverage should outperform peers with flatter order trajectories.
• Buy call spreads in OMRON for the next 3-6 months to express upside from multiple expansion while limiting exposure to near-term margin noise and component-cost volatility.
• Fade healthcare-as-a-drag concerns by avoiding shorts tied to the legacy healthcare segment alone; the segment is more likely a funding offset than a value destruction driver over the next 12 months.
• If supply-chain or Middle East headlines worsen, use any additional 5-8% drawdown to add to longs rather than chase strength; the trade should be built on order visibility, not quarterly earnings quality.